<DOC>
	<DOCNO>NCT00998335</DOCNO>
	<brief_summary>The optimal insulin therapy T2DM controversial impact nonalcoholic fatty liver disease ( NAFLD ) systematically study , particular , never use new insulin formulation detemir ( Levemir® ) aspart ( Novolog® ) . This study determine effect hepatic steatosis insulin secretion/action lower fast plasma glucose ( FPG ) target daily basal insulin detemir alone combine insulin detemir premeal insulin aspart patient uncontrolled type 2 diabetes mellitus ( T2DM ) . In first 3 month investigator optimize metabolic control patient intensive basal ( bedtime ) detemir insulin aim normal fast plasma glucose . After treatment period , patient randomize second 3 month 2:1 ratio insulin detemir detemir plus aspart . The investigator propose insulin improve day-long glycemic control A1c , reduce hepatic steatosis ( NAFLD ) ( primary endpoint ) insulin secretion/sensitivity well tolerate cause minimal weight gain hypoglycemia ( secondary endpoint ) . The study allow assess additional benefit add pre-meal rapid-acting insulin aspart basal insulin endpoint .</brief_summary>
	<brief_title>Effect Basal/Pre-Meal Insulin Strategy ( Detemir/Aspart ) Insulin Secretion Action Type 2 Diabetes</brief_title>
	<detailed_description>The control hyperglycemia T2DM ameliorate metabolic abnormality T2DM whether improves hepatic steatosis examine carefully use improve insulin formulation ( long-acting insulin detemir glargine , alone combine pre-meal short-acting insulin ) . Most research study focus glycemic control without careful examination underlie mechanism , study report improve hepatic muscle insulin sensitivity . The investigator find laboratory intensified insulin therapy T2DM associate enhanced glycogen synthase fractional velocity non-oxidative glucose disposal , improvement level insulin-stimulated insulin receptor tyrosine phosphorylation , hexokinase II mRNA enzyme function , phosphatidylinositol 3-kinase ( PI 3-kinase ) associate IRS-1 , Akt phosphorylation . Our work examine hepatic steatosis insulin secretion/action , design distinguish relative contribution reduce glucotoxicity insulin sensitivity vs. beta-cell function pre-meal regular vs. NPH insulin . It possible beneficial effect insulin therapy reduce plasma glucose FFA concentration may offset excessive hyperinsulinemia weight gain use insulins suboptimal pharmacokinetics compare new insulin formulation . Insulin detemir insulin analogue approve 2005 FDA . It long-acting insulin analogue show predictable achieve therapeutic plasma insulin level compare NPH insulin . This associated several clinical benefit , good glycemic control , less hypoglycemia , modest weight gain good quality life patient type 2 diabetes . If gluco-lipotoxicity likely play important role development hepatic steatosis ( NAFLD ) T2DM investigator speculate reverse strategy basal long-acting insulin ( insulin detemir ) alone , combine rapid-acting analog ( pre-meal insulin aspart ) may good strategy treatment T2DM .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin degludec , insulin aspart drug combination</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Insulin Detemir</mesh_term>
	<mesh_term>Insulin Aspart</mesh_term>
	<mesh_term>Insulin , Long-Acting</mesh_term>
	<criteria>To participate patient must : 1 . Be able communicate meaningfully Investigator legally competent provide write informed consent . 2 . Female patient must nonlactating must either least two year postmenopausal , use adequate contraceptive precaution ( i.e . oral contraceptive , approve hormonal implant , intrauterine device , diaphragm spermicide , condom spermicide ) , surgically sterilize ( i.e . bilateral tubal ligation , bilateral oophorectomy ) . Female patient undergone hysterectomy eligible participation study . Female patient ( except patient undergone hysterectomy bilateral oophorectomy ) eligible negative pregnancy test throughout study period . 3 . Age range 18 70 year ( inclusive ) . 4 . Patients must stable dose allow chronic medication two month prior enter doubleblind treatment period . 5 . All participant must follow laboratory value : Hemoglobin ≥ 12 g/dl male ≥ 11 g/dl female Serum creatinine ≤ 1.5 mg/dl AST ( SGOT ) ≤ 2.5 time upper limit normal ALT ( SGPT ) ≤ 2.5 time upper limit normal Alkaline phosphatase ≤ 2.5 time upper limit normal Patients exclude follow criterion present : 1 . Individuals type 1 diabetes type 2 diabetes FPG ≥ 300 mg/dl . 2 . Subjects sulfonylureas , metformin and/or TZDs unless dose stable least 2 month prior study entry . 3 . Patients follow medication : thiazide furosemide diuretic , betablockers , chronic medication know adverse effect glucose tolerance level unless patient stable dose agent past two month entry study . Patients may take stable dos estrogens hormonal replacement therapy patient agent prior two month . Patients take systemic glucocorticoid exclude . 4 . Past ( within 1 year ) current history alcohol abuse . 5 . Patients exclude history clinically significant heart disease ( New York Heart Classification great grade II ) , peripheral vascular disease ( history claudication ) , pulmonary disease ( dyspnea exertion one flight le ; abnormal breath sound auscultation ) chronic renal failure ( serum creatinine great 1.5 mg/dl ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>Type 2 diabetes mellitus</keyword>
	<keyword>Insulin therapy</keyword>
	<keyword>Detemir ( Levemir )</keyword>
	<keyword>Aspart ( Novolog )</keyword>
	<keyword>Hepatic steatosis</keyword>
</DOC>